Shares of Akorn (NASDAQ: AKRX), a generic drug manufacturer, are getting beaten down following a hint that an acquisition announced last April simply won't happen. The news has pressured Akorn's stock ...

Investors might want to bet on Akorn (AKRX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most ...

Akorn has had a busy two years in court following a flurry of data integrity woes that led former merger partner Fresenius to walk away from their deal. Now, it’s putting one issue to rest by settling ...

Akorn CEO Douglas Boothe was given the task of turning the generics company around after its $4.3 billion buyout deal with Fresenius was snatched off the table. But the clock is ticking for Boothe and ...

Add Yahoo as a preferred source to see more of our stories on Google. BERLIN (Reuters) - German healthcare group Fresenius SE (FREG.DE) said it had decided to pull out of its planned acquisition of ...

(Reuters) - Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for ...

Akorn, an Illinois-based pharmaceutical company, has agreed to pay $7.9 million to resolve allegations that it caused Medicare to pay false claims, according to the U.S. Department of Justice.

Akorn has recalled all the drugs sold under its brand or sold under other brands. DAVID J. NEAL dneal@miamiherald.com Check any prescription or over-the-counter drugs taken by you or your pets. If any ...

Despite disagreeing with accusations that it fails to comply with regulatory practices, Akorn is something of a full employment act for Food and Drug Administration inspectors. The agency released ...

LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug ...

Shares of Akorn (NASDAQ: AKRX) , a generic drug manufacturer, are getting beaten down following a hint that an acquisition announced last April simply won't happen. The news has pressured Akorn's ...